ERBB2 and breast cancer: The SUVmax ratio of HER2-positive breast cancer brain metastases was significantly greater than the SUVmax ratio of HER2-negative breast cancer brain metastases (3.98 vs 1.79, U = 38.00, p = 0.008), as presented in Figs. 1, 2, 3.